Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-01-02

Study Completion Date

2026-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Relapsed/refractory acute lymphoblastic leukemia remains a challenge in the context of limited access to immunotherapy in developing countries. With such poor 5-year overall survival rates of 10%, the investigators need strategies that surpass the complete response rate achieved in this setting, which does not exceed 60% effectiveness with different regimens, and to eventually transfer patients to hematopoietic stem cell transplantation.

In this context, the investigators are studyng if the use of venetoclax, a BCL2 inhibitor, with the use of a cytochrome p450 inhibitor such as itraconazole, alongside the TACL chemotherapy regimen, which is based on the combination of asparaginase, dexamethasone, bortezomib, vincristine, and mitoxantrone.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Venetoclax Based Regimen for R/R T-ALL

NCT05149378

Acute T-Lymphocytic Leukemia

COMPLETED PHASE2

Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic Leukemia

NCT03455517

Chronic Myeloid Leukemia

COMPLETED PHASE2

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT05105841

Chronic Lymphocytic Leukemia (CLL) Small Lymphocytic Lymphoma (SLL)

COMPLETED PHASE2

Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT03874052

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome Recurrent Acute Myeloid Leukemia Recurrent Secondary Acute Myeloid Leukemia +2 more

RECRUITING PHASE1

Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia

NCT03755947

B-Cell Chronic Lymphocytic Leukemia B-Cell Chronic Lymphocytic Leukemia in Relapse (Diagnosis)

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Response rates for salvage regimens vary depending on the patient's performance status (suitable or unsuitable for high-intensity chemotherapy), whether the patient is refractory (40%), in early or late first relapse (up to 60%), and in second or later relapse, where complete response rates decrease dramatically (as low as 10% with high-intensity regimens). Post-refractory OS has been reported at 5 months, with an EFS of 4.7 months. For patients in first relapse, the reported studies range from 5.8 months for those receiving salvage chemotherapy alone, increasing to 10 months if they undergo hematopoietic progenitor cell transplantation. For second relapses or relapses after transplantation, OS does not exceed 5 months. For patients who do not receive any treatment, the prognosis is grim, with high mortality within the following months following refractoriness or relapse without any support. 30,31,32

Therefore, it is proposed to increase the complete response rate with a pediatric-inspired chemotherapy regimen in conjunction with a BCL-2 inhibitor, so that patients can be transitioned to allogeneic bone marrow transplantation (the only curative therapy in this context), either after the treatment received or with short-term immunotherapy bridging to transplantation.

The risks associated with conventional salvage chemotherapy for patients with good performance status will not differ significantly from those typically observed in daily clinical practice (see below for the expected description of adverse events), since the basis of therapy remains the TACL regimen. A higher degree of cytopenias, especially neutropenia and thrombocytopenia, can be expected with the addition of a BCL-2 inhibitor.

Salvage chemotherapy will be assigned as follows:

* Venetoclax 100 mg orally every day for 7 days
* Itraconazole 100 mg orally every 12 hours for 7 days
* Vincristine 1.4 mg/m2 intravenously on days 1, 8, 15, and 22
* Mitoxantrone 6 mg/m2 intravenously on day 1
* L-Asparaginase 6,000 IU/m2 intramuscularly on days 5, 7, 9, 11, 13, 16, 18, 20, and 23
* Dexamethasone 20 mg orally from days 1 to 15
* Bortezomib 2 mg subcutaneously on days 1, 4, 8, and 11
* Rituximab 375 mg/m2 intravenously on day 8 for patients with CD20+, more than 20% expression in flow cytometry
* Intrathecal Chemotherapy or CNS (-): Days 8 and 15 or CNS (+): Days 1, 8, 15, and 22

The proposed chemotherapy regimen will be administered orally, intravenously, intramuscularly, and subcutaneously in an outpatient setting on the previously specified days, with appointments scheduled on days 1, 8, 15, and 22 for drug administration on the fifth floor of the University Cancer Center in the Hematology Service area. General patient assessment will be conducted in the ground floor offices of the University Cancer Center's Hematology Service. Any adverse events will be reported by system and grade according to CTCAE.

After completing the salvage chemotherapy regimen, bone marrow aspiration and measurable residual disease will be assessed on day 29 of the cycle, and not beyond day 35.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Lymphobkastic Leukemia Acute Lymphoblastic Leukaemia Recurrent Philadelphia Chromosome Negative ALL

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

One arm, open-label, phase 2 study

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TACL plus low dose Venetoclax and Itraconazole

Salvage chemotherapy will be assigned as follows:

* Venetoclax 100 mg orally every day for 7 days
* Itraconazole 100 mg orally every 12 hours for 7 days
* Vincristine 1.4 mg/m2 intravenously on days 1, 8, 15, and 22
* Mitoxantrone 6 mg/m2 intravenously on day 1
* L-Asparaginase 6,000 IU/m2 intramuscularly on days 5, 7, 9, 11, 13, 16, 18, 20, and 23
* Dexamethasone 16 mg orally from days 1 to 15
* Bortezomib 2 mg subcutaneously on days 1, 4, 8, and 11
* Rituximab 375 mg/m2 intravenously on day 8 for patients with CD20+, more than 20% expression
* Intrathecal Chemotherapy or CNS (-): Days 8 and 15 or CNS (+): Days 1, 8, 15, and 22

Group Type EXPERIMENTAL

Venetoclax low dose with itraconazole

Intervention Type DRUG

The investigators will add venetoclax in low dose (100 mg) with itraconazole to the pediatric inspired regimen TACL to enchance the complete response rate

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Venetoclax low dose with itraconazole

The investigators will add venetoclax in low dose (100 mg) with itraconazole to the pediatric inspired regimen TACL to enchance the complete response rate

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* B-cell or T-cell acute lymphoblastic leukemia.
* Philadelphia chromosome negative
* Relapsed disease after any line of treatment, defined as detection of disease activity at any time after remission
* Refractory disease after first-line treatment, defined as: more than 5% blasts after completion of induction/consolidation by flow cytometry
* Not having included venetoclax in any prior regimen.
* No prior organ damage, defined as the absence of any serious, life-threatening disease prior to the start of treatment.
* Performance status defined by the ECOG scale between 0 and 2.

Exclusion Criteria

* Isolated CNS relapse.
* Performance status defined by ECOG scale between 3 and 4.
* CTCAE-classified sensory or motor neuropathy of grade 3 or higher.
* History of hypersensitivity or intolerance to the drugs included in the regimen.
* Prior organ damage, defined as the presence of any serious, life-threatening illness prior to the start of treatment.

Minimum Eligible Age

16 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No